Breast cancer blog, articles, stories, and research.
MammaPrint evaluates the expression of 70 genes associated with breast cancer behavior and recurrence risk. MammaPrint High Risk tumors are more likely to benefit from chemotherapy than Low Risk tumors.
Hearing the words “you need a biopsy” or “we Read More
After a diagnosis of early-stage hormone receptor–positive (HR+) and Read More
What Does Your Breast Cancer Genomic Test Really Tell Read More
How these tests can help create a treatment plan Read More
The endocrine system is a series of glands responsible Read More
If you or a loved one has been diagnosed Read More
Along with surgery or radiation therapy, chemotherapy is one Read More
Breast cancer is the most common cancer among women, Read More
Contact
For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com
Fax: (844) 711-9132
For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com
©2026 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.
CHIEF COMPLIANCE OFFICER
Stephanie has worked in compliance since 2005 and has extensive experience developing and managing programs to support compliance with global, federal, and state laws and regulations in the healthcare and biotech industries. Prior to joining Agendia, Stephanie spent a significant portion of her career serving as a compliance officer in laboratories, such as HealthTrackRx, NeoGenomics, and Myriad Genetics, and held compliance leadership roles in medical device, pharma, and large health systems.
Stephanie graduated Summa Cum Laude with a B.S. in Healthcare Administration from Northern Illinois University and is Certified in Healthcare Compliance (CHC), Data Privacy (CHP), Research Compliance (CHRC), and is a Certified Internal Auditor (CIA).
